Frank Witney Buys Shares of LAB
Frank Witney purchased 99,116 shares of LAB on June 18, 2026.
Key Points
- Frank Witney bought 99,116 shares of LAB on June 18, 2026, with the stock trading around $0.77.
- LAB has significant institutional interest, with Casdin Capital holding 88.8 million shares and Viking Global Investors holding 58.7 million shares.
- Analysts from TD Cowen and Jefferies have initiated buy ratings with price targets as high as $4.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Frank Witney recently bought 99,116 shares of LAB on June 18, 2026. The purchase was not part of a pre-arranged trading plan. On Wednesday, LAB shares were trading at approximately $0.77.
Insider Buying and Selling at Standard BioTools Inc.
In addition to Frank Witney's purchase, other insiders have been active in buying LAB shares. Sean MacKay, the SVP & Chief Business Officer, acquired 500,000 shares on June 20, 2026. On June 18, 2026, Eloi Fenel bought 175,923 shares, while Troy Cox and Thomas Carey purchased 99,116 and 263,884 shares, respectively.
Other Institutional Activity in LAB
Institutional investors have shown varied activity in LAB. Casdin Capital, LLC holds a substantial position with 88,783,856 shares valued at about $81.6 million. Viking Global Investors LP has 58,651,170 shares worth approximately $53.9 million. MAK Capital One LLC increased its holdings by 6,884,468 shares, reaching a total of 26,172,626 shares valued at $24.1 million, marking a 35.7% increase. BlackRock, Inc. slightly reduced its stake by 759,849 shares, bringing its total to 24,756,084 shares valued at $22.8 million, a decrease of 3.0%. Long Focus Capital Management, LLC boosted its holdings by 3,337,318 shares, totaling 16,015,721 shares worth $14.7 million, a 26.3% increase. Vanguard Capital Management LLC opened a new position with 12,816,070 shares valued at $11.8 million.
Analysts Set New Price Targets
Analysts have been updating their views on LAB. On November 5, 2025, TD Cowen maintained a hold rating with a price target of $1.35. Previously, TD Cowen initiated a buy rating with a $3.50 target on April 16, 2024. Jefferies also started coverage with a buy rating and a $3.25 target on April 4, 2024. KeyBanc initiated a buy rating with a $4.00 target on July 12, 2023.
Bottom Line
Frank Witney's recent purchase of LAB shares highlights ongoing insider interest in the company. Institutional investors are also active, with some increasing their stakes significantly. Analyst ratings suggest mixed views, with some initiating buy ratings with high price targets. As always, these trades and ratings reflect past decisions and do not necessarily indicate current sentiment or future performance.
Get Standard BioTools Inc. alerts
New 13F filings, insider trades, and analyst moves on $LAB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.